Marisa Wexler, MS,  senior science writer—

The United States Food and Drug Administration (FDA) has approved Valtoco (diazepam nasal spray) as a rescue treatment for acute, repetitive seizures (seizure clusters) in people with epilepsy, ages 6 and older. “Cluster or acute repetitive seizures are challenging to treat and highly disruptive in the…

Since Jan. 6, physicians in England are able to prescribe the oral cannabidiol solution Epidyolex, in combination with clobazam, to treat persistent seizures in eligible people with Dravet syndrome and Lennox Gastaut…

StrideBio and Sarepta Therapeutics announced a collaboration and license agreement to advance gene therapies for rare diseases of the central nervous and neuromuscular systems, including Dravet syndrome. Many genetic conditions are caused by mutations that impair the function of a particular gene — for instance, about three-quarters of Dravet…

The U.S. Federal Trade Commission (FTC) sent warning letters to three companies that sell cannabis-based products containing cannabidiol (CBD), cautioning them that making unsubstantiated claims about the health benefits of CBD could lead to legal action. The agency “urges the companies to review all claims made for their…

The first patient has been enrolled in the BUTTERFLY study, which aims to characterize features of Dravet syndrome in children and adolescents. The announcement was made in a press release by Stoke Therapeutics, the company that is funding the study. BUTTERFLY is an observational study, which means…